BMRN
BioMarin Pharmaceutical Inc.NASDAQHealthcare$55.50-3.04%OpenMarket Cap: $10.67B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.75
P/S
3.31
EV/EBITDA
17.46
DCF Value
$11.28
FCF Yield
6.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.1%
Operating Margin
16.6%
Net Margin
10.8%
ROE
5.8%
ROA
4.9%
ROIC
5.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $874.6M | 66.3% | $79.4M | $-46.6M | $-0.22 | — |
| FY 2025 | $3.22B | 77.1% | $533.5M | $348.9M | $1.80 | — |
| Q4 2025 | $-2.35B | 81.2% | $-454.1M | $-368.7M | $-1.88 | — |
| Q3 2025 | $776.1M | 82.0% | $-46.7M | $-30.7M | $-0.16 | — |
| FY 2025 | $0.00 | NaN% | $0.00 | $26.8M | $0.14 | — |
| Q2 2025 | $825.4M | 81.8% | $276.9M | $240.5M | $1.23 | — |
| Q1 2025 | $745.1M | 79.7% | $223.9M | $185.7M | $0.95 | — |
| Q4 2024 | $747.3M | 81.8% | $161.4M | $124.9M | $0.64 | — |
| FY 2024 | $2.85B | 79.7% | $484.2M | $426.9M | $2.21 | — |
| Q3 2024 | $745.7M | 74.7% | $113.9M | $106.1M | $0.55 | — |
| Q2 2024 | $712.0M | 81.7% | $120.5M | $107.2M | $0.55 | — |
| Q1 2024 | $648.8M | 80.7% | $88.5M | $88.7M | $0.46 | — |